46 results about "In vitro analysis" patented technology

<heading lvl="0">Abstract of Disclosure</heading> A small volume sensor, and methods of making, for determining the concentration of an analyte, such as glucose or lactate, in a biological fluid, such as blood or serum, using techniques such as coulometry, amperometry, and potentiometry. The sensor includes a working electrode and a counter electrode, and can include an insertion monitoring trace to determine correct positioning of the sensor in a connector.

In vitro electrochemical sensor that provide accurate and repeatable analysis of a sample of biological fluid are provided. In some embodiments, the sensors have a measurement zone that has a volume less than the volume of the sample chamber. The measurement zone could have a volume of no more than about 0.2 μL.

A wireless capsule as a disease diagnosis tool in vivo can be introduced into a biological body by a native and/or artificial open, or endoscope, or an injection. The information obtained from a micro-spectrometer, and/or an imaging system, or a micro-biosensor, all of which are built-in a wireless capsule, can be transmitted to the outside of the biological body for medical diagnoses. In addition, a real-time specimen collection device is integrated with the diagnostic system for the in-depth in vitro analysis

A sensor utilizing a non-leachable or diffusible redox mediator is described. The sensor includes a sample chamber to hold a sample in electrolytic contact with a working electrode, and in at least some instances, the sensor also contains a non-leachable or a diffusible second electron transfer agent. The sensor and/or the methods used produce a sensor signal in response to the analyte that can be distinguished from a background signal caused by the mediator. The invention can be used to determine the concentration of a biomolecule, such as glucose or lactate, in a biological fluid, such as blood or serum, using techniques such as coulometry, amperometry, and potentiometry. An enzyme capable of catalyzing the electrooxidation or electroreduction of the biomolecule is typically provided as a second electron transfer agent.

The invention relates to a method for the molecular diagnosis of prostate cancer, comprising the in vitro analysis of the overexpression or underexpression of combinations of genes that can distinguish, with high statistical significance, tumorous prostate samples from non-tumorous prostate samples. The invention also relates to a kit for the molecular diagnosis of prostate cancer, which can perform the above-mentioned detection.

A protein capable of transporting organic anions having amino acid sequences represented by SEQ ID NO: 1 or 2 or amino acid sequences derived therefrom by deletion, substitution or addition of one or more amino acid residues; and a gene coding for the protein. The protein and gene therefore are useful in vitro analysis of drug release and drug—drug interactions and development of method for screening drugs useful for preventing nephrotoxicity.

Method and device for the in vitro analysis of mRNA of genes involved in hematological neoplasias. The device, composed of probes which specifically hybridize with genes involved in hematological neoplasias, designed so that its behaviour in the hybridization is similar, permits the evaluation of the mRNA level in biological samples taken from subjects suspected to be suffering from hematological neoplasia and facilitating the comparison between the different samples and their grouping by similarity in the gene expression patterns, especially when the probes are disposed in the form of microarray. The application of the method of the invention to obtain and process data of gene expression differences from the device of the invention permits the identification of genes significant for distinguishing samples associated to hematological neoplasias, facilitates the diagnosis of neoplasias as CLL and permits making a prognosis of the evolution thereof.

An in vitro method of determining an analyte concentration of a sample includes placing the sample into a low-field, bench-top time-domain nuclear magnetic resonance (TD-NMR) spectrometer. The NMR spectrometer is tuned to measure a selected type of atom. A magnetic field is applied to the sample using a fixed, permanent magnet. At least one 90 degree radio-frequency pulse is applied to the sample. The radio-frequency pulse is generally perpendicular to the magnetic field. The 90 degree radio-frequency pulse is removed from the sample so as to produce a decaying NMR signal. The decaying NMR signal is measured at a plurality of times while applying a plurality of 180 degree refocusing radio-frequency pulses to the sample. The analyte concentration is calculated from the plurality of measurements associated with the decaying NMR signal and a selected model.

The invention discloses applications of a small molecular compound Salubrinal in drugs for treating or preventing osteoporosis and osteopenia diseases. Through the utilization of a mouse model of postmenopausal osteoporosis caused by OVX ovariectomy, a mouse model of disuse osteoporosis caused by tail suspension, in vivo and in vitro analysis of primary bone marrow-derived cells and the indicationof cell line-based experimental results, Salubrinal administration can effectively relieve OVX related symptoms, stimulate the differentiation of osteoblasts and inhibit the development of osteoclasts. Through the indication of precise molecular mechanism of the Salubrinal, the Salubrinal can be applied to drugs for treating or preventing osteopenia diseases caused by postmenopausal osteoporosis,disuse osteoporosis and other factors.

The invention relates to the technical field of biological preserving fluid, in particular to cell preserving fluid for in-vitro analysis and detection and a preparation method thereof. The cell preserving fluid is prepared from the following components in a concentration range: 60 to 75 v/v percent of a cell fixing agent, 0.6 to 0.9 g/100 mL of an osmotic pressure regulator, 0.2 to 0.5 g/100 mL of an anticoagulant, 0.3 to 0.6 g/100 mL of chitosan quaternary ammonium salt and 0.05 to 0.2 g/100 mL of trehalose; and the solvent is ultra-pure water, and the pH value is 7.0-7.6. A small amount of trehalose and chitosan quaternary ammonium salt are combined, so that the protective effect can be effectively enhanced, autolysis decay of cells is effectively reduced, and the integrity of cell preservation is improved. When the cell preserving fluid is prepared, ultra-pure water is used for dissolving components except the cell curing agent, the dissolving effect of the components can be effectively improved, the uniform and stable cell preserving fluid is obtained, and batch production of the cell preserving fluid is facilitated.

The invention belongs to the technical field of quantum dot fluorescent probe fluorescence detection, and especially relates to an application of a quantum dot fluorescent probe in visual detection ofHg < 2 + > in cells and human blood. The quantum dot fluorescent probe comprises silicon dioxide microspheres and 10Ca/6Tb: Bi2O2S nanocrystalline and aminated fluorescent carbon quantum dots, wherein the surface of the silicon dioxide microspheres is aminated and then is modified with a layer of 10Ca/6Tb: Bi2O2S nanocrystal, and the outer layer of the 10Ca/6Tb: Bi2O2S nanocrystal is further coated and modified with aminated fluorescent carbon quantum dots. The quantum dot fluorescent probe adopts SiO2 (at) 10Ca/6Tb: SiO2 (at) 10Ca/6Tb fluorescent probe, dual emission fluorescence can be realized, the quantum dot fluorescent probe can be used for a ratiometric fluorescence analysis method and does not depend on expensive instruments when being used for in-vitro analysis and can completelyperform quantitative or semi-quantitative analysis by naked eyes, can detect the fluorescence ratio intensity under two emission wavelengths or excitation wavelengths, can well correct errors causedby environment detection and improves the signal intensity.

The invention relates to a method for analyzing an intermediate product of secondary rearrangement of an Igk gene and a kit. The kit consists of an artificially designed oligodeoxynucleotide linker, 6 pairs of upstream primers and a downstream primer; a first rearrangement fragment VkJk-intron-RS which is replaced in the secondary rearrangement of the Igk gene is captured and amplified by using a ligation mediated-PCR (lm-pcr) technology. The kit disclosed by the invention can be applied to in vitro analysis of the generation efficiency of the secondary rearrangement of the Igk gene and research on a molecular mechanism which generates the secondary rearrangement of the Igk gene.

Systems and methods of in vivo and in vitro radical protein foot-printing using an opto-fluidic array are presented. These teachings may be used to, for example, study three-dimensional protein structure or bio-kinetics. Radical dosimetry including an optional intrinsic standard is used. Real-time feedback based on an internal standard provides comparability between different experiments and in vivo and in vitro analysis results in data that is representative of actual biological conditions.

Described are interdigitated electrodes, which may optionally be plasmonic, useful for in vitro biosensing applications. Such devices may significantly reduce undesired background noise by separating the excitation source (light) from the detection signal (current), and thereby, leading to higher sensitivity for bioanalysis compared with conventional interdigitated electrodes. Also described are methods of making such interdigitated electrodes, which allow a substrate, which may optionally be plasmonic, to be tuned not only to maximize the targeted interaction of the cells with the nanoscale geometry, but also for the excitation wavelength to minimize biological sample interference.